Clinical Case Database / Category: Patient Management

Management of retinal vein occlusion

Publication details

Dr. Kieran O'Kane, Mr. Saju Thomas
Foundation Years Journal, volume 9, issue 6, p.29 (123Doc Education, London, June 2015)

Abstract

Retinal vein occlusions are categorised based on the location of the thrombus and subsequent haemorrhages, and whether this has caused ischaemia. Treatment options vary based on the type of vein occlusion and ischaemic status and include observation, laser treatment and intravitreal injections. Prognosis varies from complete resolution of vision to painful and sight threatening complications.

Access the Clinical Cases Database

A subscription is required to read the full article. Please subscribe using one of the options below.

Authors

Dr. Kieran O'Kane

County Durham and Darlington Foundation Trust, DL3 6HX
kieranokane@doctors.org.uk

Mr. Saju Thomas (Corresponding author)

Consultant Ophthalmic Surgeon/Specialist in Retinal Diseases
County Durham and Darlington Foundation Trust, DL3 6HX
sajuthomas@doctors.org.uk

References

1. Rogers, S; McIntosh, RL; Cheung, N; Lim, L; Wang, JJ; Mitchell, P; Kowalski, JW; Nguyen, H; Wong, TY. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. http://researchonline.lshtm.ac.uk/1983/
2. Yau JW, Lee P, Wong TY, Best J, Jenkins A. Retinal vein occlusion: an approach to diagnosis, systemic risk factors and management. http://www.ncbi.nlm.nih.gov/pubmed/19120547
3. Kanski J, Clinical Ophthalmology: A Systematic Approach, 5th Ed. Butterworth Heniemann 2003, 455-462.
4. Klein R, Klein BE, Moss SE, Meuer SM. The epidemiology of Retinal Vein Occlusion: The Beaver Dam Eye Study. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1298220/
5. Retinal Vein Occlusion (RVO) Guidelines, The Royal College Of Ophthalmologists, 2015
6. Elkington AR, Frank HJ, Greaney MJ, Clinical Optics, 3rd Ed. Blackwell Publishing 2006, 209-210
7. Brown DM, Campochiaro PA, Bhisitkul RB, Ho AC, Gray S, Saroj N et al. Sustained benefits from Ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology 2011; 118(8): 1594-602
8. Campochiaro PA, Brown DM, Awh CC, Lee SY, Gray S et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology 2011; 118(10):2041-9
9. NICE Technology appraisal guidance [TA283] Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion. https://www.nice.org.uk/guidance/ta283
10. Korobelnik JF, Holz FG, Roider J, Ogura Y et al. Intravitreal Aflibercept injection for macular edema resulting from central retinal vein occlusion. One-year results of the phase 3 GALILEO Study. Ophthalmology 2014; 121:202-208
11. Brown DM, Heier JS, Clark WL, et al. Intravitreal Aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the Phase 3 COPERNICUS Study. Am J Ophthalmic 2013;155(3):429-437
12. NICE Technology Appraisal Guidance [TA305] Aflibercept for treating visual impairment caused by macular oedema secondary to retinal vein occlusion. https://www.nice.org.uk/guidance/ta305
13. Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J et al. Dexamethasone intravitreal implant in patients with macular oedema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology 2011; 118(12):2453-60
14. NICE Technology Appraisal Guidance [TA 229] Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusion. https://www.nice.org.uk/guidance/ta229

Disclaimers

Conflict Of Interest

The Journal requires that authors disclose any potential conflict of interest that they may have. This is clearly stated in the Journal’s published “Guidelines for Authors”. The Journal follows the Guidelines against Conflict of Interest published in the Uniform Requirements for Manuscripts Submitted to Biomedical Journals (http://www.icmje.org/urm_full.pdf).

Financial Statement

The authors of this article have not been paid. The Journal is financed by subscriptions and advertising. The Journal does not receive money from any other sources. The decision to accept or refuse this article for publication was free from financial considerations and was solely the responsibility of the Editorial Panel and Editor-in-Chief.

Patient Consent statement

All pictures and investigations shown in this article are shown with the patients’ consent. We require Authors to maintain patients’ anonymity and to obtain consent to report investigations and pictures involving human subjects when anonymity may be compromised. The Journal follows the Guidelines of the Uniform Requirements for Manuscripts (http://www.icmje.org/urm_full.pdf). The Journal requires in its Guidelines for Authors a statement from Authors that “the subject gave informed consent”.

Animal & Human Rights

When reporting experiments on human subjects, the Journal requires authors to indicate whether the procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the HelsinkiDeclaration of 1975, as revised in 2008.

About the Clinical Cases Database

T​he Foundation Years Clinical Cases Database is​ a selection of 600 peer-reviewed clinical cases in the field of patient safety and clinical practice, specifically focused on the clinical information needs of junior doctors, based around the Foundation Year Curriculum programme (MMC). The cases have been chosen to align with the Foundation Year Curriculum.

The database is fully searchable, or can be browsed by medical specialty. Abstracts can be read free of charge, however a subscription is required in order to read the complete cases.